Mavyret 50 mg/1

Mavyret 50 mg/1 is a combination of Glecaprevir and Pibrentasvir, used for treating certain viral infections. This oral medication is manufactured by AbbVie Inc. in the USA.

Mavyret 50 mg/1 is primarily used for the treatment of chronic hepatitis C virus (HCV) infection. This medication is designed to target and inhibit the virus, helping to reduce its presence in the body. It is often prescribed as part of a comprehensive treatment plan for HCV, which may include other medications and lifestyle changes.

Common effects of Mavyret 50 mg/1 may include fatigue, headache, and nausea. Some individuals might experience changes in taste or mild gastrointestinal discomfort. These effects vary from person to person and are not experienced by everyone who takes the medication.

Mavyret 50 mg/1 should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. This medication should be kept out of reach of children and pets.

Mavyret 50 mg/1 may interact with certain medications, including those that affect liver enzymes. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other substances that affect liver function should be avoided while taking this medication.